Jinghe Biopharmaceutical Technology

Jinghe Biopharmaceutical (also known as GeneHe) is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of Adeno-associated virus (AAV) mediated gene therapies. The company targets high-prevalence diseases in ophthalmology and neurology, aiming to replace frequent protein injections with one-time genetic treatments. Its lead candidate, JH001, is an AAV-based therapy for neovascular age-related macular degeneration (nAMD) that has entered clinical trials. Jinghe Biopharmaceutical leverages a proprietary platform for vector optimization and large-scale GMP manufacturing. The firm is supported by leading investors such as IDG Capital and Sequoia China to advance its pipeline of transformative medicines.